Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing

Abstract

Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.

1 . A method of treating metastasis or inhibiting metastasis in a subject having a cancer comprising administering to the subject an amount of an inhibitor of KIF19 or of an inhibitor of Kif19 gene product, or an inhibitor of CEP192 or of an inhibitor of Cep192 gene product, effective to treat metastasis or inhibit metastasis. 
     
     
         2 . (canceled) 
     
     
         3 . A method of treating fibrosis or scarring, or of inhibiting fibrosis or scarring, in a subject comprising administering to the subject an amount of an inhibitor of KIF19 or of an inhibitor of Kif19 gene product, or an inhibitor of CEP192 or of an inhibitor of Cep192 gene product, effective to treat fibrosis or scarring, or inhibit fibrosis or scarring. 
     
     
         4 . (canceled) 
     
     
         5 . A method of treating pain associated with wound healing in a subject having a wound comprising administering to the subject an amount of an inhibitor of CEP192 or of an inhibitor of Cep192 gene product effective to treat pain associated with wound healing. 
     
     
         6 . The method of  claim 1 , wherein the KIF19 or Kif19 gene product is a human KIF19 or human Kif19 gene product, respectively. 
     
     
         7 . The method of  claim 1 , wherein the CEP192 or Cep192 gene product is a human CEP192 or a human Cep192 gene product, respectively. 
     
     
         8 . The method of  claim 1 , wherein the inhibitor of KIF19 is an RNAi nucleic acid. 
     
     
         9 . The method of  claim 1 , wherein the inhibitor of CEP192 is an RNAi nucleic acid. 
     
     
         10 . The method of  claim 8 , wherein the RNAi nucleic acid is a siRNA directed to KIF19 or a shRNA directed to KIF19. 
     
     
         11 . The method of  claim 9 , wherein the RNAi nucleic acid is a siRNA directed to CEP192 or a shRNA directed to CEP192. 
     
     
         12 .- 18 . (canceled) 
     
     
         19 . The method of  claim 1 , wherein the cancer is a thyroid, blood, bladder, breast, colorectal, kidney, lung, melanoma, ovary, pancreas, prostate or stomach cancer. 
     
     
         20 .- 21 . (canceled) 
     
     
         22 . The method of  claim 3 , wherein the fibrosis is in response to an injury. 
     
     
         23 . (canceled) 
     
     
         24 . The method of  claim 3 , wherein the scarring is skin scarring, cardiovascular scarring, cardiac tissue scarring or neuronal scarring. 
     
     
         25 . The method of  claim 5 , wherein the wound is a skin wound, cardiovascular wound, cardiac tissue scarring or neuronal wound. 
     
     
         26 . The method of  claim 25 , wherein the skin wound is a burn wound. 
     
     
         27 .- 43 . (canceled) 
     
     
         44 . The method of  claim 3 , wherein the inhibitor is a siRNA directed to KIF19 or CEP192, or a shRNA directed to KIF19 or CEP192. 
     
     
         45 . The method of  claim 5 , wherein the inhibitor is a siRNA directed to KIF19 or CEP192, or a shRNA directed to KIF19 or CEP192.